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PURPOSE. To describe foveal sparing (FS) in central retinal dystrophies (RD).
METHODS. Participants for this retrospective study were identified from the retinal dystrophy
database of the Department of Ophthalmology at Radboud University Medical Center. FS was
defined as an intact foveal structure surrounded by at least 1808 of chorioretinal atrophy, and a
best-corrected visual acuity (BCVA) of <1.0 logMAR (>20/200 Snellen). Eligible eyes were
identified using fundus autofluorescence (FAF) images, and FS was confirmed using near-
infrared reflectance (NIR) imaging and spectral-domain optical coherence tomography when
available. Clinical and demographic data were extracted from medical records. We performed
quantification of FS and chorioretinal atrophic areas using semiautomated software on fundus
autofluorescence and NIR images. We calculated the chronologic change using eye-wise linear
regression.
RESULTS. We identified 36 patients (56 eyes) with FS. RDs included: Stargardt disease
(STGD1;20 patients), central areolar choroidal dystrophy (CACD; 7 patients), mitochondrial
retinal dystrophy (MRD; 6 patients), pseudo-Stargardt pattern dystrophy (PSPD; 3 patients).
Median age at first presentation was 60 (interquartile range [IQR] 54–63) years. Median BCVA
at first presentation ranged from 20/25 Snellen in STGD1, to 20/38 Snellen in MRD.
Progression of the chorioretinal atrophic area ranged from 0.26 (0.25–0.28) mm/year in PSPD,
to 0.14 (0.11–0.22) in CACD. Change in FS area over time was similar between the different
dystrophies.
CONCLUSIONS. The presence of FS in different RDs suggests a disease-independent mechanism
that prolongs the survival of the fovea. The associated preservation of BCVA is important for
the individual prognosis and has implications for the design of therapeutic trials for RDs.
Keywords: foveal sparing, retinal dystrophy, Stargardt disease, central areolar choroidal
dystrophy, mitochondrial retinal dystrophy
Retinal dystrophies (RDs) are among the leading causes forlegal blindness in industrial countries.1–3 Despite differenc-
es in underlying mechanisms, the common pathway in these
disorders involves a selective atrophy of outer retinal layers,
retinal pigment epithelium and associated choroidal layers,
functionally paralleled by the development of absolute scoto-
mas.4
Typically, patches of chorioretinal atrophy initially occur in
the parafoveal retina. With spread over time, multifocal
atrophic areas coalesce, and new atrophic areas may occur.
On clinical examination, the fovea may remain uninvolved from
chorioretinal atrophy until late in the course of the disease,
when the fovea finally becomes atrophic. This phenomenon is
referred to as ‘‘foveal sparing,’’5–9 and can be observed in
several RDs, such as autosomal recessive Stargardt disease
(STGD1),8,10–13 central areolar choroidal dystrophy (CACD),14
and maternally inherited diabetes and deafness (MIDD).15,16
Geographic atrophy and reticular pseudo-drusen in age-related
macular degeneration may also show a tendency to spare the
fovea for a prolonged period of time.7,9,17–20
Although there is no consensus definition of the term
‘‘foveal sparing,’’ it could be distinguished from a perimacular
ring scotoma, which is located more peripherally in the macula,
resulting in a central visual island frequently observed in
retinitis pigmentosa (RP).21 Bull’s eye maculopathy is another
separate entity, where an intact fovea is surrounded by a—
usually oval shaped—area of outer retinal atrophy.
Historically, the term ‘‘foveal sparing’’ was coined by Hart et
al.22 to describe the sparing of the fovea from hemifield defects.
In the context of macular disorders, Hart et al.22 were the first
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to describe a ‘‘sparing of foveal sensitivity in macular disease,’’
while Sarks et al.7 specified an ‘‘enlargement and coalescence
of atrophy into an almost complete ring around the fovea.7’’
These perimetric and funduscopic terms were brought
together by Sunness et al.20 using the term ‘‘foveal sparing’’,
defined as an intact foveal structure surrounded by outer
retinal and RPE atrophy. The atrophy may either arrange as
multiple independent spots, or in a ring or horseshoe-like
fashion.20
The etiology of foveal sparing remains unclear, but it is
highly remarkable that such a distinct preservation of the
central macular tissue occurs in a variety of heterogenic retinal
disorders. This suggests that the underlying mechanism of
foveal sparing is, to a certain degree, disease-independent.
To date, the manifestations of foveal sparing in retinal
dystrophies has not been analyzed systematically. Knowledge
regarding the natural history of this peculiar phenomenon
becomes even more important in the light of emerging
therapeutic modalities aimed at prevention or slowing down
of progressive chorioretinal atrophy in RDs (e.g.,
NCT01367444, NCT01736592, NCT01469832, and
NCT02402660 on www.clinicaltrials.gov). A better understand-
ing of the disease course of foveal sparing enables better
stratification when including patients into a clinical trial and
allows for a tailor-made prognosis. In addition, insight in the
underlying mechanisms resulting in foveal sparing could open
up new avenues for therapeutic approaches aimed at foveal
preservation. In this study, we will provide a detailed
description of foveal sparing in a large cohort of RD patients.
We will analyze commonalities and discriminating features
among the different RDs, and we will discuss the consequence
for pathophysiological mechanisms regarding foveal sparing.
METHODS
Patient Selection
For this retrospective study, we employed the RD database of
the Department of Ophthalmology at Radboud University
Medical Center. The 1800 patients in this database have all
been diagnosed with some form of inherited retinal disease,
the large majority of which have been analyzed genetically. To
readily identify patients with foveal sparing, we limited our
search to patients with at least one fundus autofluorescence
(FAF) imaging investigation. A genetically confirmed clinical
diagnosis was also a requirement to be included in the search.
In the context of this study, the foveal sparing had to fulfill two
criteria. First, the fovea had to be surrounded by at least 1808 of
chorioretinal atrophy.6,8,9 Second, a best-corrected visual
acuity (BCVA) of 1.0 logMAR (‡ 20/200 Snellen) had to be
present.8 Both eyes of a patient were included unless foveal
sparing was only present in one of them.
The goal of the research is to study chorioretinal atrophy
localized to the posterior pole, therefore we excluded
generalized chorioretinal atrophy disorders like; retinitis
pigmentosa, choroideremia, Bietti crystalline dystrophy, and
gyrate atrophy. We excluded retinopathies with solely loss of
photoreceptors encircling the fovea, like in Bull’s eye
maculopathy, because these entities do not fulfill the criteria
of chorioretinal loss.
This retrospective study was approved by the Institutional
Ethics Committee at Radboud University Medical Center
(Nijmegen, The Netherlands), and was performed in accor-
dance with the Tenets of the Declaration of Helsinki. All
patients provided informed consent prior to additional
ophthalmologic examinations to complete the clinical assess-
ment and blood collection.
Clinical Data and Image Acquisition
A detailed medical and ophthalmologic history, including
historical BCVA data, age at onset, age at diagnosis, and initial
symptoms, was obtained from the medical records. Age at
onset was defined as the age at which the patient first
experienced visual complaints. In asymptomatic persons and
patients where the age at onset could not be determined, the
age at disease onset was considered equivalent to the age at
diagnosis.
Standard imaging protocols were followed in the acquisition
of retinal images. The FAF and NIR images were acquired using
an HRAþOCT device (Spectralis; Heidelberg Engineering,
Heidelberg, Germany). The field of view was set to 308 3 308
or 558 3 558 with a minimum resolution of 768 3 768 pixels
and centered on the macula. Single images were automatically
aligned and averaged to maximize the signal-to-noise ratio
using the manufacturer’s software (automatic real-time [ART]-
mode, Heidelberg Eye Explorer, Heidelberg Engineering). The
spectral-domain optical coherence tomography (SD-OCT)
scans were performed with the same device, and up to 100
single images were averaged to improve image quality. SD-OCT
scans were 6.3 mm horizontal line scans through the fovea and
follow-up mode was used for follow-up images. Furthermore,
color fundus photographs (CFP) were obtained using a Topcon
TRC50IX retinal camera (Topcon Corporation, Tokyo, Japan).
Image Grading
Qualitative Assessment. Atrophy of retinal pigment
epithelium and outer retina is typically associated by a sharply
demarcated zone of dramatic reduction of autofluorescence
(analogous to the previously employed definition of ‘‘definitely
decreased autofluorescence’’).23 Where available, SD-OCT was
used to confirm foveal outer retinal integrity. If foveal sparing
was lost during follow-up, all later visits were excluded from
the analysis.
Qualitative assessment of the available FAF and SD-OCT
images was performed to identify characteristic morphologic
features and atrophy patterns. In this explorative study, image
analysis was performed by one trained reader (ML). As a result
of the retrospective nature of this dataset, some of the image
grading tasks could not be performed in every eye or for every
visit, because image availability varied per patient visit.
Quantitative Assessment. Measurements of atrophic area
and foveal sparing area were performed as previously
described,9,24 using imaging software (RegionFinder, version
2.5.5.0; Heidelberg Engineering). In brief, the dramatic
decrease of the FAF signal in GA areas compared with
nonatrophic retinal areas is used by the imaging software
(Heidelberg Engineering) for the segmentation of atrophy
areas. The examiner/operator is required to define the center
of each atrophic area. The software’s so-called ‘‘region-growing
algorithm’’ then identifies the borders of each atrophic area by
the sharp change in signal intensity between atrophic and
nonatrophic retina. This employed version of the imaging
software (Heidelberg Engineering) includes a feature that
automatically registers FAF to corresponding NIR images and
allows the operator to easily switch from one modality to the
other, thereby semi-automating the quantification of RPE
atrophy and foveal sparing areas. In case no NIR images were
available, measurements were only performed if the atrophy
could be clearly discriminated from the physiologically
decreased foveal autofluorescence due to the physiological
attenuation of the autofluorescence signal in the foveal area by
macular pigment. Atrophy measurements were performed in
either 308 3 308 or 558 3 558 images within a single eye, as the
software does not allow for quantitative comparison between
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images of different sizes. Only areas of sharply demarcated RPE
atrophy, or ‘‘definitely decreased autofluorescence’’ (DDAF),
were quantified, and quantification of foveal sparing required
an area of DDAF surrounding the fovea by at least 2708.9
Therefore, the foveal sparing area was not quantified in eyes
with horseshoe-shaped atrophy surrounding the fovea by
<2708. In case of incomplete foveal sparing, a constraint was
placed by manually drawing a line at the narrowest place of the
incomplete part of the residual foveal island.
Subfoveal retinal thickness (SRT) was assessed in SD-OCT
scans, transversing the foveola, as the distance between the
internal limiting membrane (ILM) and the outer border of OCT
band 4 (corresponding to the RPE/Bruch’s membrane com-
plex),25 using a ‘‘distance tool’’ (Heidelberg Eye Explorer;
Heidelberg Engineering). A representative example is given in
Supplementary Figure 1. Furthermore, the integrity of the
retinal bands at the fovea was assessed.
As a result of the retrospective nature of this study, some of
the image grading tasks could not be performed in every eye or
for every visit, because image availability varied per patient
visit.
Genetic Analysis
All samples were processed by the Department of Human
Genetics of the Radboud University Medical Center in
Nijmegen, The Netherlands. Genetic testing was targeted
conform the clinical diagnosis.
Stargardt disease (STGD1): ABCA4 analysis was performed
using arrayed primer extension analysis (APEX) microarrays
(Asper Biotech, Tartu, Estonia) and Sanger sequencing
validation. The presence of two variants in the ABCA4 gene
confirmed the diagnosis STGD1. In cases where only one
variant in ABCA4 was identified, but the phenotype was
characteristic for STGD1, this was deemed sufficient for the
diagnosis. The following genetic variants were defined as
severe: protein-truncating, canonical splice-site variants, as
well as deletions spanning at least one exon. In case of
missense variants, severity was predicted by bioinformatic
TABLE 1. Summary of Patient Characteristics
Stargardt
Disease
Central Areolar
Choroidal Dystrophy
Mitochondrial
Retinal Dystrophy Pseudo-Stargardt
Patients in database, n 176 103 21 36
Patients with foveal sparing, n (%) 20 (11.4) 7 (6.8) 6 (28.6) 3 (8.3)
Male–female ratio, n:n 10:10 4:3 1:5 0:3
Median age at first presentation, y 60.08 (54.72–62.12) 56.13 (52.74–59.36) 57.64 (53.4–64.21) 61.71 (61.65–64.40)
Median age at diagnosis, y 57.31 (45.18–61.71) 55.98 (48.51–58.58) 58.21 (54.44–64.35) 61.72 (61.65–64.4)
Median time to diagnosis after
symptoms onset, y
1.60 (0.11–5.15) 0.76 (0.30–2.26; data from
6 patients)
5.97 (2.71–13.90) 14.91 (11.71–37.69)
Patients with bilateral foveal
sparing, n (%)
11 (55) 3 (42.9) 4 (66.6) 2 (66.6)
Initial complaint, n
Decreased VA 14 4 5 3
Diplopia 0 2 0 0
Metamorphopsia 4 3 0 0
Scotoma 0 1 0 0
None 1 0 0 0
Unknown 1 0 1 0
Some patients mentioned two initial complaints.
FIGURE 1. Longitudinal retinal imaging of a representative eye with STGD1. Serial fundus autofluorescence images (upper row), and SD-OCT scans
centered on the fovea (lower row), of a representative right eye with foveal sparing in a patient with STGD1. Multiple atrophic lesions may be seen
that coalesce over time. Cystoid lesions in the inner retina (asterisks) and elevation of the borders of outer retinal atrophy (arrowheads) may be
seen. Location of the SD-OCT scan is indicated by the green line.
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FIGURE 2. Retinal imaging of two representative CACD cases. FAF, near-infrared reflectance and SD-OCT scans of the left eyes of two patients with
CACD. Foveal sparing may demarcate only poorly on FAF. Arrow: center of the foveal pit. Yellow bar: areas of intact retinal pigment epithelium in
proximity to the foveal depression. Location of the SD-OCT scan is indicated by the green line.
FIGURE 3. Longitudinal retinal imaging of a representative eye with mitochondrial retinal dystrophy (MRD). The left eye of a patient with MRD
showing gradual contraction of the remaining foveal island in 21 months. Fundus autofluorescence (FAF, upper row) and near-infrared reflectance
(lower row) demonstrate retinal pigment epithelium atrophy encircling the fovea by 3608. The relatively spared fovea almost exactly centers on the
foveal depression, as also shown by the SD-OCT scan (position is indicated by green line).
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means (SIFT, Polyphen, MutationTaster, and CADD). Cases with
a clinical Stargardt-like phenotype and a mutation in the
PRPH2 gene, with or without an additional variant in a single
ABCA4 allele, were considered having pseudo-Stargardt
pattern dystrophy (PSPD).26
Central areolar choroidal dystrophy (CACD): analysis of
PRPH2 was conducted using Sanger sequencing. One variant
in the PRPH2 gene, combined with the typical CACD
phenotype, was considered sufficient to establish the diagno-
sis.
Mitochondrial retinal dystrophy (MRD): mitochondrial DNA
was screened for mutations. The presence of the m.3243A>G
mitochondrial mutation, combined with a characteristic
clinical picture and visual symptoms, was required for the
diagnosis of mitochondrial retinal dystrophy.
Statistical Analysis
R version 3.3.0 was used to perform statistical analysis.
Decimal-scale visual acuity data were converted to logMAR.
The rate of atrophy progression, and foveal sparing area loss
over time, were calculated by eye wise linear regression from
square-root transformed values, to reduce the dependency of
enlargement rates on baseline lesion size, as previously
suggested.27 In this retrospective analysis, data for these
parameters were not available for every single visit in every
patient. To avoid exclusion of all data from a particular visit in
case of a single missing parameter, subsets of visits were
analyzed, when necessary. In these cases, cohort sizes and
observation intervals were calculated separately. Unless stated
differently, all data given represent medians and corresponding
interquartile ranges. In this exploratory analysis, statistical tests
for significance were not performed.
RESULTS
A total of 336 patients from the database of 1800 patients met
the search criteria: FAF images and a genetically confirmed
clinical diagnosis. In this cohort of 336 patients, we identified
36 individuals (56 eyes) with foveal sparing as previously
defined. In 20 patients (56%), foveal sparing was present or
developed in both eyes. Overall, this cohort included 20 of 176
(11.4%) STGD1 patients (31 eyes), 7 of 103 (6.8%) patients
diagnosed with CACD (10 eyes), 6 of 21 (28.6%) MRD cases (10
eyes), 3 of 36 (8.3%) PSPD patients (5 eyes). A comprehensive
overview of all patient characteristics is provided in Table 1.
Retinal images of foveal sparing in each of the conditions are
depicted in Figures 1 through 4.
FIGURE 4. Retinal imaging of two representative PSPD. Fundus autofluorescence (left) and near-infrared reflectance image (right) of two right eyes
of patients with PSPD. Multifocal areas of macular atrophy are usually observed in conjunction with more peripheral atrophic spots. Spectral-domain
optical coherence tomography (inset, centered on the fovea) discloses outer retinal atrophy and disruption of retinal structure. The yellow bar
indicates preservation of the retinal pigment epithelium.
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Baseline
There was little variability in the age at first clinical
presentation among the different RDs included. Median age
at first presentation was 60 (54–63) years. Median values
ranged from 56 years in CACD to 62 in PSPD (Table 1).
Variability in the duration from experienced symptoms onset
to the time where a dystrophy was diagnosed was more
pronounced, with median values ranging from 0.8 (0.3–2.3)
years in CACD to 15 (12–38) years in PSPD (Table 1).
At first presentation, median BCVA values were relatively
high, ranging from 0.11 (0.09–0.26) logMAR (20/25 [20/24–
20/36] Snellen) in STGD1, to 0.28 (0.15–0.30) logMAR (20/38
[20/28–20/39] Snellen) in MRD.
Qualitative assessment of the available FAF and SD-OCT
images revealed characteristic features of foveal sparing
morphology and atrophy progression. At baseline (first visit),
foveal sparing was present in 52 eyes of 36 patients (bilateral in
15 patients). Thirty-two eyes (62%) presented with a multifocal
atrophy pattern (e.g., Fig. 1), 15 eyes (29%) presented with a
horseshoe-type pattern (e.g., Fig. 1), and we observed a solitary
foveal island in 5 eyes (e.g., Fig. 3). Sixteen eyes did not show
sufficient atrophic changes to warrant the diagnosis and in six
eyes there may have been foveal sparing, but at the time of
investigation the foveal tissue was already lost. We compared
both eyes in these 36 patients. We observed a high degree of
symmetry between both eyes in individual patients: in MRD
and PSPD, foveal sparing could be observed bilaterally in 66.6%
of cases. Slightly lower values of 55% and 43% were found in
STGD1 and CACD (Table 1).
Follow-Up
Over time, BCVA remained relatively stable when grouped
according to underlying conditions. Decline of BCVA was most
noticeable in STGD1 and PSPD, with a loss of 0.11 (0.01–0.13),
and 0.13 (0.06–0.15) logMAR, respectively.
Follow-up was available in 21 patients (58%). Of the 16 eyes
without foveal sparing at baseline, five eyes developed foveal
sparing over a median period of 3 years (range, 1–4 years). We
noticed this development only in STGD1 patients, and in none
of the other conditions. Foveal sparing was lost during follow-
up in five eyes over a median period of 5 years (range, 3–8
years). In four of these eyes, a multifocal pattern was present at
baseline, and foveal sparing was initially not present in one
eye.
In all conditions, we noticed three distinct and consecutive
patterns of atrophy, starting with multifocal atrophic lesions
FIGURE 5. Foveal sparing atrophy progression pattern. Fundus autofluorescence images of the right (A–C) and left (D–F) eye of a Stargardt patient
with asymmetrical foveal sparing. Multifocal areas of RPE atrophy (A) develop and coalesce over time, forming a horseshoe-type atrophy pattern (B).
In the last picture (C) the isthmus is severed leaving an isolated foveal island. The left eye reveals a similarly progressive atrophy pattern, albeit in an
earlier stage. Figure 5C reprinted from van Huet RAC, Bax NM, Westeneng-Van Haaften SC, et al. Foveal sparing in Stargardt disease. Invest
Ophthalmol Vis Sci. 2014;55:7467–7478.  2014 The Association for Research in Vision and Ophthalmology, Inc. Figure 5E reprinted from
Westeneng-van Haaften SC, Boon CJ, Cremers FP, Hoefsloot LH, den Hollander AI, Hoyng CB. Clinical and genetic characteristics of late-onset
Stargardt’s disease. Ophthalmology. 2012;119:1199–1210. Copyright  2012 American Academy of Ophthalmology.
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immediately adjacent to the fovea, to a horseshoe-type pattern
into an isolated foveal island before the occurrence of central
atrophy. Figure 5 shows these four stages in the progression of
foveal sparing in both eyes of a patient with STGD1.
Atrophy progression rates varied between 0.26 (0.25–0.28)
mm/year in PSPD, to 0.14 (0.11–0.22) mm/year in CACD (Fig.
6A). Loss of surface area of the spared fovea ranged from 0.06
(0.08–0.02) mm/year in STGD1 to 0.10 (0.15–0.10) mm/year in
MRD (Fig. 6B), and loss of SRT ranged from 13.84 (19.92–9.47)
lm/year in MRD to 0.90 (5.13–1.50) lm/year in CACD.
A summary of all BCVA measurements and quantitative
retinal image analyses can be found in Table 2.
Genetic Analysis
An overview of all genetic variants is given in Table 3. In only
six of twenty STGD1 cases (30%), two ABCA4 variants were
detected. The most prevalent variant is c.5461-10T>C (5/26¼
19%). At least one severe ABCA4 variant was detected in 19
cases (95%). In all CACD cases, the same PRPH2 missense
variant (p.Arg142Trp) was identified. Likewise, in all MRD
cases, the same variant (m.3243A>G) was detected in the
mitochondrial DNA.
DISCUSSION
Foveal sparing is a regularly encountered phenomenon in a
variety of retinal disorders, including RDs like STGD1 and
geographic atrophy in age-related macular degeneration. This
study analyses the characteristics of foveal sparing in a wide
range of retinal dystrophies, including STGD1, CACD, MRD,
and PSPD. All the patients were in their fifth decade or older at
first presentation, indicating that foveal sparing mainly
manifests in RD patients with a relatively low rate of
progression, where visual loss occurs later in life. The
manifestation of foveal sparing in this heterogenic group of
disorders is remarkably similar, in particular with regard to the
kinetics of atrophy progression toward the fovea, which varies
only slightly between disorder types. In general, RPE atrophy
in foveal sparing progresses in a relatively fixed pattern,
starting with small, multifocal areas of atrophy that surround
the fovea. These, then gradually expand in all directions and
coalesce, forming a horseshoe-type atrophy. The bridge of
retinal tissue connecting the fovea to the non-atrophic part of
the macula gradually narrows until this isthmus disappears,
leaving a solitary foveal island. In the final stage this island is
lost to atrophy. This sequence of steps is a common finding in
these patients and can be of great prognostic help, although
the rate of progression may differ. This pattern of RPE atrophy
was symmetrical in 80% of the bilateral cases. This indicates, as
already suggested by others,28 that the fellow eye cannot
automatically serve as control in therapeutic intervention trials
for RDs in patients with foveal sparing.
Although the frequency of foveal sparing in our cohort was
highest in the MRD group (29%), this was much lower than the
previously reported number of 84% in a 2013 study by de Laat
et al.16 This may be an underestimation on our side due to
inclusion bias since this study was not primarily designed to
estimate the prevalence of foveal sparing in RDs, including
MRD.
To date, the underlying mechanism of foveal sparing is
incompletely understood. Disease independent factors are
likely at play in view of the high heterogeneity of the
underlying disorders. This notion is supported by the virtually
identical kinetics of atrophy progression toward the fovea
observed among most conditions (0.06–0.10 mm/year). The
presence of multifocal areas of chorioretinal atrophy surround-
ing the fovea, and very similar square-root transformed atrophy
progression rates of 0.116 mm/year were observed in age-
related macular degeneration.9,28 The similarities between the
phenomenon of foveal sparing in monogenic and multifactorial
disorders further supports the hypothesis of disease-indepen-
dent mechanisms that shape the foveal sparing phenotype.
The general susceptibility to retinal degeneration may lie in
metabolic differences between regions of the macula. Those
differences may be associated with physical characteristics of
foveal and peripheral cones; foveal cone outer segments
physically resemble those of rods rather than peripheral cones.
Furthermore, Mu¨ller cells are short and exist in a 1:1 ratio with
foveolar cones, but are longer and have a lower ratio
extrafoveally.29
A number of underlying mechanisms have been proposed
involving the rod-derived cone viability factor (RdCVF),
variations in macular pigment and peak distribution as well
as cone density, increased vulnerability of certain parafoveal
FIGURE 6. Change of atrophy area and foveal sparing area over time.
Change of atrophy area (A) and foveal sparing area (B) over time as
measured in registered fundus autofluorescence images in eyes with
distinct retinal dystrophies and foveal sparing. Please note progression
rates were square root transformed to reduce the dependency of
enlargement rates on baseline lesion size. The horizontal bar inside
the boxes represents the median, the hinges correspond to the 25th
and 27th percentiles. The upper and the lower whiskers extend to the
largest (resp. smallest) value no further than 1.5 * IQR from the hinges.
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photoreceptors, and factors related to RPE and choroid. The
RdCVF is secreted from rod photoreceptors and protects cones
from degeneration.30 An increased sensitivity of foveal cones to
RdCVF, possibly complemented by higher secretion levels of
RdCVF, may result in improved central cone survival.
A second hypothesis involves the macular pigments: lutein,
zeaxanthin and meso-zeaxanthin. These carotenoids protect
against macular damage through their antioxidant properties
and by filtering potential harmful blue light. In eyes with foveal
sparing, an uneven distribution of macular pigment might lead
to protection of the most central photoreceptors, leaving the
parafoveal photorecepotors relativeley unprotected.31,32 An-
other explanation may lie in the highly variable peak cone
density ranging from 98,200 to 324,100 cones/mm2. This
remarkable interindividual variability is much less pronounced
in the area surrounding the fovea and may contribute to the
phenomenon of foveal sparing.33 In vivo determination of cone
density with adaptive optics could solve the role of peak cone
density in foveal sparing. Another factor that may be of
influence is the increased vulnerability to age and degenerative
disease of respectively rod photoreceptors and short wave-
length (blue) S-cone photoreceptors.34,35 Both rods and S-
cones are absent in the foveal center and the increased
susceptibility to aging and/or disease may explain the relative
preservation of the fovea in certain patient. An explanation
may also lie in the unfavorably high ratio of rods per RPE cell in
the parafoveal retina that could lead to an earlier decompen-
sation of metabolic function promoting perifoveal atrophy.16,36
Finally, the unique choroidal blood supply to the fovea has
been put forward as a factor leading to a local protective
effect.37,38
A common finding in these foveal sparing patients is late age
at which the diagnosis is made. The well-preserved visual
acuity leads to patient’s delay and at the time of the first
ophthalmologic consultation large areas of atrophy are already
present. We know from this and other studies that the atrophy
progression rate is relatively slow,39–41 disease-specific changes
have therefore been present for years. In the 37 patients with
foveal sparing in this study, only one patient experienced a
scotoma as initial symptom. The large majority (n ¼ 26; 72%)
patients present with loss of visual acuity. This late recognition
of patients with foveal sparing RDs narrows the window of
opportunity for therapeutic intervention, which is becoming
increasingly important as novel therapeutic approaches
emerge (NCT01367444, NCT01736592, NCT01469832, and
NCT02402660 on www.clinicaltrials.gov).
In the group of STGD1 patients, the high frequency of self-
reported ‘‘decreased visual acuity’’ as initial symptom goes
together with a high baseline visual acuity (0.11 [0.09–0.26])
logMAR (approximately 20/25 Snellen). This is likely due to the
fact that parafoveal scotomas affect high resolution visual tasks
like face recognition and reading, whereas BCVA tests rely on
the maximum resolution of the fovea.7,19,20,42 It is important to
be aware that visual acuity tests are an imperfect measurement
for macular function—in particular in patients with foveal
sparing.
Preservation of the foveal tissue in the late stage of a RD is
beneficial to the patient. The ProgSTAR study recently showed
a stable BCVA in the STGD1 cohort with foveal sparing over the
course of 3.24 years. In contrast, in the STGD1 cohort without
foveal sparing and equivalent baseline visual acuity, an average
loss of one line per year could be observed.43
Recently, it was shown that discrimination between foveal
sparing and nonfoveal sparing STGD1 phenotypes can be made
as early as the time the first atrophic lesions become apparent,
based on parameters like a late age-at-onset and thinning of the
outer nuclear layer and ellipsoid zone.8,40 Yet, biomarkers that
could predict foveal sparing at an even earlier stage are not
available.
TABLE 2. Summary of Clinical and Retinal Imaging Parameters
Stargardt Disease
Central Areolar
Choroidal Dystrophy
Mitochondrial
Retinal Dystrophy Pseudo-Stargardt
n Median (IQR) n Median (IQR) n Median (IQR) n Median (IQR)
Number of eyes with foveal
sparing (total)
31 10 10 5
Eyes with longitudinal data 19 10 7 2
Follow-up time (y) 19 3.59 (1.87 to 4.48) 6 6.37 (2.94 to 7.15) 7 1.95 (1.55 to 5.51) 2 4.12 (4.12 to 4.12)
BCVA: 19 6 7 2
First visit (logMAR) 0.11 (0.09 to 0.26) 0.22 (0.13 to 0.28) 0.28 (0.15 to 0.30) 0.15 (0.11 to 0.14)
Loss to last follow-up
(logMAR)
0.00 (0.05 to 0.04) 0.01 (0.05 to 0.03) 0.00 (0.07 to 0.17) 0.15 (0.03 to 0.28)
Observation interval (y) 3.24 (1.87 to 4.61) 2.18 (1.29 to 4.14) 1.95 (1.55 to 5.03) 4.12 (4.12 to 4.12)
Atrophy size: 11 6 5 2
First visit (mm2) 3.61 (1.64 to 7.96) 6.08 (3.29 to 8.42) 27.02 (22.24 to 29.27) 3.40 (3.06 to 3.75)
Change over time
(=mm2/y)
0.22 (0.17 to 0.31) 0.14 (0.11 to 0.22) 0.23 (0.17 to 0.31) 0.26 (0.25 to 0.28)
Observation interval (y) 3.24 (2.41 to 3.96) 5.69 (2.64 to 6.40) 1.55 (1.55 to 5.96) 4.12 (4.12 to 4.12)
Foveal sparing size: 6 3 3 2
First visit (mm2) 0.42 (0.22 to 1.33) 1.16 (1.01 to 1.56) 2.19 (1.63 to 2.80) 1.27 (1.22 to 1.33)
Change over time
(=mm2/y)
0.06 (0.08 to 0.02) 0.06 (0.07 to 0.03) 0.10 (0.15 to 0.10) 0.07 (0.08 to 0.05)
Observation interval (y) 1.87 (1.41 to 2.305) 3.65 (3.65 to 5.04) 3.967 (2.54 to 6.00) 3.06 (2.53 to 3.59)
Subfoveal retinal thickness: 15 4 5 2
First visit (mm) 203 (187 to 223) 161 (138.2 to 182.5) 192 (189 to 210) 175 (160 to 190)
Change over time (mm/
y)
4.95 (11.75 to 0.40) 0.90 (5.13 to 1.50) 13.84 (19.92 to 9.47) 4.79 (5.57 to 4.01)
Observation interval (y) 2.88 (2.31 to 3.61) 4.16 (2.90 to 4.77) 1.55 (1.55 to 2.07) 4.12 (4.115 to 4.12)
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With regard to genetic predisposing factors, it has been
suggested that the presence of relative mild genetic variants
correlate with a less severe phenotype and a generally later age
of onset.11,44 In 14 of the 20 (70%) STGD1 patients with foveal
sparing, only one ABCA4 variant could be detected. The
percentage of unidentified second mutations is much lower
(30%) in patients with a typical Stargardt phenotype with an
age-at-onset in the second to third decade, a second mutation
has not been identified (Cremers FPM, unpublished observa-
tions, 2018).
Deep-intronic variants were found in several mono-allelic
cases.45–48 Very recently, the hypomorphic intronic variant
c.4253þ43G>A was found to be associated with late-onset
STGD1.49 Zernant and colleagues50 determined that
c.5603A>T (p.Asn1868Ile), previously suspected to be benign
because of its high prevalence in the general population
(minor allele frequency of 0.07), is disease-causing. This variant
was typically found in a compound heterozygous manner with
a severe ABCA4 variant in ~50% of monoallelic cases and in
~80% of late-onset STGD1 cases.50 Runhart et al.51 in addition
found significant differences in age-at-onset between affected
siblings and even nonpenetrance in three families with
asymptomatic biallelic siblings of affected persons. The
penetrance of this variant, when present together with a
severe ABCA4 variant in the other gene copy, was estimated to
be less than 5%, suggesting a crucial role for genetic or
environmental modifiers in STGD1. In the present study, the
c.5603A>T variant was found in 3/20 (17%) of STGD1 cases
TABLE 3. An Overview of All Genetic Variants in This Study Cohort
Patient
ID Gene Variant 1
Protein/
Heteroplasmy
(ID24-29) Effect Gene Variant 2 Protein Effect
1 ABCA4 c.5196þ1G>T p.(?) Severe þ
2 ABCA4 c.3734G>A p.(Ser1245Asn) Mild þ
3 ABCA4 *c.5461-10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
Severe þ
4 ABCA4 c.4506C>A p.(Cys1502*) Severe þ
5 ABCA4 c.3874C>T p.(Gln1292*) Severe ABCA4 c.3113C>T p.(Ala1038Val) Mild
6 ABCA4 c.5461–10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
Severe þ
7 ABCA4 c.5461–10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
Severe þ
8 ABCA4 c.3874C>T p.(Gln1292*) Severe ABCA4 c.5603A>T p.(Asn1868Ile) Mild
9 ABCA4 c.3874C>T p.(Gln1292*) Severe þ
10 ABCA4 c.5461–10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
Severe þ
11 ABCA4 c.5461–10T>C p.[Thr1821Valfs*13,
Thr1821Aspfs*6]
Severe þ
12 ABCA4 c.4363T>C p.(Cys1455Arg) Severe ABCA4 c.5603A>T p.(Asn1868Ile) Mild
13 ABCA4 c.1822T>C p.(Phe608Leu) Severe þ
14 ABCA4 c.768G>T p.(Leu257Valfs*17) Severe þ
15 ABCA4 c.5813T>G p.(Leu1938*) Severe ABCA4 †c.2588G>C p.[Gly863Ala,
Gly863del]
Mild
16 ABCA4 c.768G>T p.(Leu257Valfs*17) Severe þ
17 ABCA4 c.4773þ1G>A p.(?) Severe þ
18 ABCA4 c.1822T>A p.(Phe608Ile) Severe þ
19 ABCA4 c.768G>T p.(Leu257Valfs*17) Severe ABCA4 c.3113C>T p.(Ala1038Val) Mild
20 ABCA4 c.768G>T p.(Leu257Valfs*17) Severe ABCA4 c.5603A>T p.(Asn1868Ile) Mild
21 PRPH2 c.658del p.(Arg220Glyfs*36) Severe ABCA4 c.2588G>C† p.[Gly863Ala,
Gly863del]
Mild
22 PRPH2 c.441delT p.(Gly148fs*5) Severe
23 PRPH2 c.441delT p.(Gly148fs*5) Severe
24 m. m.3243A>G 85
25 m. m.3243A>G Unknown
26 m. m.3243A>G Unknown
27 m. m.3243A>G 15
28 m. m.3243A>G 11
29 m. m.3243A>G 7 ABCA4 c.4771G>A p.(Gly1591Arg) Unknown
30 PRPH2 c.424C>T p.(Arg142Trp) Mild
31 PRPH2 c.424C>T p.(Arg142Trp) Mild
32 PRPH2 c.424C>T p.(Arg142Trp) Mild
33 PRPH2 c.424C>T p.(Arg142Trp) Mild
34 PRPH2 c.424C>T p.(Arg142Trp) Mild
35 PRPH2 c.424C> T p.(Arg142Trp) Mild
36 PRPH2 c.424C>T p.(Arg142Trp) Mild
* c.5461-10T>C is found in cis with c.5603A>T, but the latter common coding variant does not contribute to the pathogenicity of this allele and
thus omitted.
† c.2588G>C is not analyzed for presence of c.5603A>T.
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with foveal sparing. In two other STGD1 cases where both
alleles were identified, mild variants (p.(Ala1038Val) and
p.[Gly863Ala, Gly863del]) were also found, corroborating the
hypothesis that late-onset STGD1 can partially be explained by
the combination of a severe with a mild ABCA4 variant.
Therapeutic approaches for RDs are currently emerging.
Recently, the Food and Drug Administration (FDA) approved
gene therapy for RPE65-associated retinal dystrophy, a form of
Leber congenital amaurosis. In addition, therapy trials for
STGD1, choroideremia, Usher syndrome type 2A and several
more are underway (NCT01367444, NCT01736592,
NCT01469832, and NCT02402660 on www.clinicaltrials.
gov). To accurately assess efficacy of new therapeutic
modalities in clinical trials, careful patient selection and well-
thought out outcome measures are essential.52 Eyes with foveal
sparing could be candidates for inclusion into clinical trials,
due to the clearly demarcated, well-measurable areas of
progressive RPE atrophy and preserved BCVA, allowing for
visual stabilization as one of the outcome measurement. In
addition, in about half of the patients with foveal sparing, this
phenomenon occurs in both eyes, which opens the opportu-
nity of inter-eye comparison. Finally, these patients may benefit
greatly from successful therapeutic intervention, as prolonged
preservation of the fovea is paramount to daily functioning,
and by extension to quality of life. The use of eyes with foveal
sparing for clinical trials inevitably also comes with certain
pitfalls. A long follow-up period would be necessary to
accurately assess treatment effect if BCVA is used as parameter.
And in our cohort, only 43% of the cases has a symmetrical
disease progression. In such cases, an alternative outcome
measure like atrophy progression, or change in the size of the
spared fovea over time, is preferable.41
In summary, the phenomenon of foveal sparing was
observed in several distinct retinal dystrophies. All patients
presented with late-onset disease, and the pattern of perifoveal
RPE atrophy progression was identical in all conditions.
Remarkable similarities between foveal sparing pattern in
RDs and age-related macular degeneration may suggest disease-
independent mechanisms to shape the pattern of foveal
sparing. Importantly, the observations made in this study will
allow ophthalmologists to provide affected patients with a
more accurate prognosis, and the characteristic aspects in
terms of visual function loss and atrophy progression should be
considered when including foveal-sparing and non-foveal
sparing eyes in clinical trials.
Further research, including histopathology studies and
detailed retinal imaging with adaptive optics, is necessary to
elucidate the mechanisms involved in foveal sparing. The new
insights gleaned from these studies might pave the way for
new disease-independent (gene-)therapeutic approaches for
prolonged preservation of foveal tissue in degenerative retinal
disease.
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